Electra Therapeutics (ETRA) eyes $325 million Nasdaq IPO at $14 to $16
As seen on the 24/7 Wall St. homepage on September 14, 2026.
Electra Therapeutics sets $14-$16 range for $325 million Nasdaq IPO
Electra Therapeutics just put numbers on its Nasdaq debut: 21.7 million shares at $14 to $16, or about $325 million, one of the larger biotech raises of the year. Jefferies, TD Cowen, Evercore ISI and Cantor are running the books, so pricing is likely days away.
Continue ReadingShow less
Electra Therapeutics has filed an amended prospectus setting the terms for its initial public offering: 21.7 million shares priced between $14 and $16, pointing to a deal worth roughly $325 million. That scale puts it among the larger biotech raises of the year, a meaningful signal in a market where many clinical-stage companies have struggled to clear the IPO bar at all.
The offering is being led by a heavyweight syndicate of Jefferies, TD Cowen, Evercore ISI, and Cantor. When four bulge-bracket or top-tier specialty banks share the books on a biotech deal of this size, it generally signals strong institutional pre-marketing and a compressed path to pricing.
Disclosure
*$149 for two years (or $1.43 per week) is an introductory promotion for new members only. 62% discount based on the current list price of Stock Advisor of $199/year. Membership will renew at the then-current list price at the end of the membership term. Stock Advisor returns are 930% as compared to the S&P 500 returns of 185% as of April 7, 2026.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
The amended filing, made public on September 14, 2026, indicates that the company and its underwriters have already gone through at least one round of terms-setting, which is typical as the deal is refined based on early investor feedback during the roadshow. Pricing is expected within days of the amendment becoming public.
The company is set to trade on Nasdaq. Investors watching the biotech IPO pipeline will want to track how the final price lands relative to the $14 to $16 range, as pricing above the midpoint would reflect robust demand while a deal priced at the low end or below would tell a different story about appetite for new clinical-stage issuance.
Mentioned: ETRA